Nifty MNC

LG Electronics India has informed that the Board of Directors of the Company, at its meeting held today, Thursday, November 05, 2026, has considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. The said financial results have been limited reviewed by the Statutory Auditors of the Company and the Limited Review Report issued thereon is enclosed; Approved the proposal to enter into a new line of business, namely, the Vehicle Solutions Business, encompassing manufacturing, assembling, importing, exporting, distributing, trading, selling, supplying, installing, integrating, servicing, maintaining and providing solutions relating to automotive and mobility technologies, products, components, systems and software, as more particularly described in the proposed alteration to the Objects Clause of the Memorandum of Association of the Company. The details required under Regulation 30 of the SEBI Listing Regulations read with the applicable provisions of the SEBI Master Circular dated January 30, 2026, in respect of the adoption of the new line of business are enclosed as Annexure-A; and alteration of the Objects Clause of the Memorandum of Association (MOA).

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, LG Electronics India has enclosed the Press Release being issued by the Company, titled, ‘LG Electronics India Continues Strong Momentum -Delivers Highest Growth Post Listing in Q2 FY27’. This intimation is also being uploaded on the Company’s website at https://www.lg.com/in/investorrelations/quarterly-reports/

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), LG Electronics India has informed that the Board of Directors of the Company, at its meeting held today i.e. Thursday, November 05, 2026, has considered and approved the alteration of the Objects Clause of the Memorandum of Association (MOA) of the Company by insertion of a new Sub-clause 7 under the Main Objects of Clause III(A), to enable the Company to undertake the Vehicle Solutions Business, as detailed in the proposed Postal Ballot Notice, subject to the approval of the shareholders of the Company through Postal Ballot.

The above information is a part of company’s filings submitted to BSE.

Gland Pharma has informed that it enclosed announcement regarding the receipt of USFDA approval for Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL and 80 mg/mL Single-Dose Vials and 200 mg/5 mL (40 mg/mL), 400 mg/10 mL (40 mg/mL), and 400 mg/5 mL (80 mg/mL) Multiple-Dose Vials.

The above information is a part of company’s filings submitted to BSE.